Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sandoz records year-on-year constant currency growth in 2015

Sandoz records year-on-year constant currency growth in 2015

28th January 2016

Sandoz has experienced strong underlying growth in 2015, according to new financial results reported by parent company Novartis.

Its net sales total of $9.2 billion (6.4 billion pounds) represents a year-on-year increase of seven percent on a constant currency basis, with volume growth of 15 percentage points more than offsetting eight percentage points of price erosion.

All of its key operating regions grew during the period, led by the US, Western Europe, Asia Pacific and Latin America, while in business unit terms the strongest momentum was produced by its biopharmaceuticals division, which delivered constant currency growth of 39 percent.

Key highlights of the period included the submission of the company's new biosimilar versions of etanercept and pegfilgrastim in Europe and the US respectively. In the coming year, Novartis expects the Sandoz business to deliver low to mid-single digit growth.

It was also announced in the report that Jeff George, who spent five years leading the Sandoz business until May 2014, will be leaving the Novartis group and stepping away from his position in charge of fellow Novartis business unit Alcon.ADNFCR-8000103-ID-801811289-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.